Showing results (21-30 of 37) with videos related to
Sort By:
Pageof 4
Diabetes, Obesity & Metabolism|September 4, 2023
Efficacy and safety of cetagliptin as monotherapy in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled phase 3 trialLinong Ji, Jinmiao Lu, Leili Gao, et al.Diabetes, Obesity & Metabolism|August 22, 2025
Efficacy and safety of chiglitazar add-on to metformin in type 2 diabetes mellitus (RECAM study)Leili Gao, Linong Ji, Xin Yan, et al.Current Medical Research and Opinion|September 5, 2024
Efficacy and safety of insulin degludec biosimilar B01411 versus originator insulin degludec in Chinese patients with type 2 diabetes inadequately controlled on oral antidiabetic drugs: a multicenter, randomized, open-label, phase 3 studyLinong Ji, Leili Gao, Zhifeng Cheng, et al.Diabetes, Obesity & Metabolism|September 19, 2023
A randomized, double-blind, placebo controlled, phase 3 trial to evaluate the efficacy and safety of cetagliptin added to ongoing metformin therapy in patients with uncontrolled type 2 diabetes with metformin monotherapyLinong Ji, Jinmiao Lu, Leili Gao, et al.Journal of Diabetes Investigation|November 21, 2025
Efficacy and safety of insulin degludec/insulin aspart biosimilar B01711 vs originator insulin degludec/insulin aspart in Chinese patients with type 2 diabetes inadequately controlled on basal or premixed insulin: A multicenter, randomized, open-label, phase 3 studyLeili Gao, Zhifeng Cheng, Guoqing Ma, et al.Journal of Diabetes|April 25, 2020
Patient characteristics and 6-month dose of basal insulin associated with HbA1c achievement <7.0% in Chinese people with type 2 diabetes: results from the Observational Registry of Basal Insulin Treatment (ORBIT)Leili Gao, Puhong Zhang, Jianping Weng, et al.Diabetes|March 20, 2023
A Comparison of Daily Glucose Fluctuation Between GCK-MODY and Type 2 Diabetes Using Continuous Glucose Monitoring TechnologyQian Ren, Ping Zhang, Wuyan Pang, et al.Diabetes, Obesity & Metabolism|November 26, 2022
Efficacy and safety of janagliflozin as add-on therapy to metformin in Chinese patients with type 2 diabetes inadequately controlled with metformin alone: A multicentre, randomized, double-blind, placebo-controlled, phase 3 trialLeili Gao, Zhifeng Cheng, Benli Su, et al.JAMA|June 7, 2026
Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical TrialLeili Gao, Hongwei Jiang, Hanqing Cai, et al.Scientific Reports|August 21, 2019
Serum Albumin, but not Bilirubin, is Associated with Diabetic Chronic Vascular Complications in a Chinese Type 2 Diabetic PopulationYu Zhu, Xiaoling Cai, Yan Liu, et al.Pageof 4